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Abstract The human paraoxonase (PON) gene family con-
sists of three members, PON1, PON2, and PON3, aligned
next to each other on chromosome 7. By far the most-stud-
ied member of the family is the serum paraoxonase 1
(PON1), a high-density lipoprotein-associated esterase/lac-
tonase. Early research focused on its capability to hy-
drolyze toxic organophosphates, and its name derives from
one of its most commonly used in vitro substrates, paraoxon.
Studies in the last 2 decades have demonstrated PON1’s
ability to protect against atherosclerosis by hydrolyzing
specific derivatives of oxidized cholesterol and/or phos-
pholipids in oxidized low-density lipoprotein and in athero-
sclerotic lesions. Levels and genetic variability of PON1
influence sensitivity to specific insecticides and nerve agents,
as well as the risk of cardiovascular disease. More re-
cently, the other two members of the PON family, PON2
and PON3, have also been shown to have antioxidant
properties. A major goal in present research on the paraox-
onases is to identify their natural substrates and to eluci-
date the mechanism(s) of their catalytic activities.
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Introduction
Mazur (1946) was the first to describe the enzymatic hy-
drolysis of organophosphorus compounds by animal tis-
sues, and, during the 1950s, Aldridge (1953a, 1953b) stud-
ied the hydrolysis of paraoxon in human blood serum and
sera from several other mammalian species. Aldridge pro-
posed that these esterases, capable of hydrolyzing organo-
phosphates as well as aromatic esters, such as p-nitro-
phenyl acetate, be called “A-esterases” (e.g., paraoxonase),
to distinguish them from the “B-esterases”, represented by
the serine carboxylesterases and cholinesterases that are
inhibited by paraoxon and other organophosphates. Hu-
man serum paraoxonase (PON1) can hydrolyze the toxic
oxon metabolites of a number of insecticides such as
parathion, diazinon and chlorpyriphos (La Du 1992), and
even nerve agents such as sarin and soman (Broomfield
and Ford 1991, Davies et al. 1996; see Fig. 1a, b). The
presence of the PON1 enzyme in the blood, liver and
some other tissues should provide some protection against
chronic exposure to low levels of organophosphates, and
have the advantage that the enzyme acts catalytically,
rather than binding them stoichiometrically as the B-es-
terases do. However, PON1’s catalytic efficiency with most
organophosphates is low (see Table 1), so enzymatic hy-
drolysis provides only limited protection against acute ex-
posure. For example, paraoxon given to mice lacking PON1
has about the same toxicity as it has in wild-type mice (Li
et al. 2000). However, with some other organophosphates,
such as diazoxon and chlorpyrifos oxon, PON1 has 10 and
20 times higher catalytic efficiencies, respectively, than
with paraoxon, so PON1 seems to make a significant dif-
ference in their toxicities (Li et al. 2000).
Among the aromatic ester substrates for PON1 are phe-
nylacetate, thiophenylacetate, and 2-naphthylacetate (La Du
1992; Fig. 1c). A variety of aromatic and aliphatic lactones
as well as cyclic carbonates are also hydrolyzed by PON1,
e.g. homogentisic acid lactone, dihydrocoumarin, γ-butyro-
lactone, and homocysteine thiolactone (Billecke et al.
2000; Jakubowski 2000) (Fig. 1d). PON1 also catalyzes
the reverse reaction, lactonization, of γ- and δ-hydroxy-
carboxylic acids (Teiber et al. 2003).
In 1996, it was established that the gene responsible for
paraoxonase/arylesterase activities described above (PON1),
is a member of a multigene family (Primo-Parmo et al.
1996). Three such esterases (PON1, PON2 and PON3) have
been identified to date, and these were named in the order
of their discovery. Human PON2 and PON3 lack, or have
very limited, paraoxonase and arylesterase activities, but
are similar to PON1 in that both hydrolyze aromatic and
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long-chain aliphatic lactones, e.g. dihydrocoumarin and 
5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-HETE)
lactone (D. Draganov, J. Teiber, B.N. La Du, unpublished
data). Since lactones are common constituents of plants,
and are natural flavoring agents in many food products,
lactonase activity may represent an important common
feature of the PON enzymes. Protection against dietary and
environmental lactones could even be a selective force re-
sponsible for maintaining the balanced polymorphisms
found in the mammalian PON enzymes. Furthermore, a
number of drugs contain lactone or cyclic carbonate moi-
eties that are metabolized by the PONs. For example,
PON1 hydrolyses the unsaturated cyclic carbonate prodrug
prulifloxacin to the active quinolone antibiotic NM394
(Tougou et al. 1998), and the rate of hydrolysis seems to
depend on the polymorphism at position 192 (see below).
PON1’s lactonase activity has been utilized in the devel-
opment of locally acting glucocorticoid drugs, which un-
dergo rapid hydrolysis and inactivation when they reach
the circulation, and thus serum PON1 prevents their un-
wanted systemic effects (Biggadike et al. 2000). PON3
hydrolyses widely used drugs such as the statin lactones




(lovastatin and simvastatin) and the diuretic spironolac-
tone (Fig. 2).
Evolution of the PON Family
Augustinsson (1968) proposed that the arylesterases arose
as an offshoot from the carboxylesterases, but differed by
having cysteine, rather than serine, as the key component
of their active centers. Although this hypothesis remained
unchallenged for many years, the extensive cloning and
sequencing of the hydrolytic enzymes made it evident that
there is no structural similarity in the amino acid sequences
of the PONs with sequences found for the mammalian
cholinesterases, carboxylesterases, or bacterial organo-
phosphatases. It was concluded that they are not related,
so other ancestral relatives had to be sought for the PON
family (LaDu et al. 1999a). Kobayashi et al. (1999) have
cloned a lactone hydrolase from the fungus Fusarium
oxysporum, which has appreciable structural homology with
human serum PON1. Furthermore, these two enzymes
share a number of substrates, such as dihydrocoumarin and
homogentisic acid lactone. Interestingly, the fungal lac-
tonase does not hydrolyze paraoxon. Other PON-like se-
quences can be found in bacteria, plants, the worm Caeno-
rhabditis elegans, and the fruit-fly Drosophila melano-
gaster. We have cloned PON-like cDNAs from the zebra-
fish (Danio regio), frog (Xenopus laevis), chicken (Gallus
gallus), turkey (Meleagris gallopavo) and a number of
mammals (Primo-Parmo et al. 1996; Draganov et al. 2000;
D. Draganov, unpublished data). A phylogenetic tree of the
vertebrate PONs is presented in Fig. 3. On the basis of the
structural homology and predicted evolutionary distance
between them, it appears that PON2 is the oldest member
of the family; PON3 arose from it next, and, more re-
cently, PON1 appeared.
Enzymatic characteristics and tissue distribution
Human PON1 is synthesized in the liver and secreted into
the blood, where it is associated exclusively with high-
density lipoprotein (HDL) (Mackness 1989a, 1989b; Has-
sett et al. 1991). Serum PON1 is a glycosylated protein of
354 amino acids with an apparent mass on SDS-PAGE of
43–47 kDa. The mature protein retains its hydrophobic leader
sequence, from which only the initial methionine is cleaved
(Hassett et al. 1991). The retained N-terminal signal pep-
tide is a structural requirement for PON1’s association with
HDL (Sorenson et al. 1999). The enzyme has two cal-
cium-binding sites with Kd values of 0.36 and 6.6 µM–1;
the higher-affinity site is essential for enzyme stability;
the other is essential for enzymatic hydrolytic activity
(Kuo and LaDu 1998). The exact amino acid residues par-
ticipating in Ca2+-binding sites remain to be defined. Se-
lective chemical modification of aspartic acid (D) and
glutamic acid (E) residues with carbodiimides prevents
Ca2+ binding and inactivates human PON1 (Josse et al.
1999). Eighteen of the conserved acidic amino acids in
human PON1 have been mutated to alanine to make sin-
gle mutants, eight of which have less than 10% of the wild
type arylesterase and paraoxonase activities: E53,1 D54,
D 169, D183, E195, D269 and D279 (Josse et al. 1999).
Except D269, none of these lie within the three putative
EF-hand-type calcium-binding sites identified in human
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Table 1 Kinetic analysis of substrate hydrolysis by purified human serum paraoxonase-1192 (PON1192) allozymes
Substrate PON1192Q PON1192R Activity ratio
Vmax Q/R
Vmax (U/mg) Km (mM) Vmax/Km Vmax (U/mg) Km (mM) Vmax/Km
Phenylacetate1 845 0.69 1225 720 0.27 2700 1.2
Paraoxon1 0.47 (0.96)2 0.50 0.94 (1.9)2 2.1 (6.1)2 0.27 7.8 (23)2 0.22 (0.16)2
Sarin3 69 0.21 330 21 0.31 68 3.3 
Soman3 82 0.42 195 31 0.25 124 2.6
γ-Butyrolactone4 420 15 23 290 5.3 55 1.4
Dihydrocoumarin4 180 0.022 8200 160 0.013 12300 1.1
1From Smolen et al. (1991)
2Vmax in presence of 1 M NaCl in brackets, Km values remained the same
3From Broomfield and Ford (1991)
4From Billecke et al. (2000)




1 The numbering of the amino acid residues in this review is in accord
with the recommendations of the Third International Meeting on Es-
terases Reacting with Organophosphorus Compounds (Dubrovnik,
Croatia, April 1998) (La Du et al. 1999b) and starts with the initial
Met. Thus the numbering in the text may differ by +1 with some of the
original references in which the numbering starts from Ala2 (the first
amino acid in the secreted protein). Also we refer to one of the PON1
promoter polymorphisms as T(–108)C rather than –107 number used
by R.W. James’ group.
and rabbit PON1 (Kuo and LaDu 1998), suggesting that
Ca-binding residues are dispersed in the primary structure
(Josse et al. 1999). Removal of Ca2+ by chelating agents
irreversibly destroys PON1 activity and stability, whereas
some divalent ions (Zn, Mn, Mg) can keep PON1 in a sta-
ble, although inactive form (Kuo and LaDu 1998). PON1
has three cysteine(C) residues (at positions 42, 284 and
353); the first and third form a disulfide linkage but
residue 284 is free (Kuo and La Du 1995; see Fig. 4). Site-
directed mutagenesis of C42 or C353 to alanine leads to
PON1 inactivation and significantly reduces secretion (Josse
et al. 1999). Mutating C284 to alanine or serine decreases,
but does not abolish the paraoxonase and arylesterase ac-
tivities (Sorenson et al. 1995b). In contrast, Aviram et al.
(1998) have demonstrated that Ca2+ is not essential, but
the C284 is required for PON1’s ability to protect low-
density protein (LDL) against copper-induced oxidation.
This led to the speculation that PON1 possesses two cat-
alytic sites – one for the hydrolytic activities, and another
for the antioxidant activity (Aviram et al. 1998, Aviram
1999). Using group-selective labeling and site-directed
mutagenesis, Josse et al. (1999) have identified additional
amino acid residues essential for PON1 esterase activities:
H115, H134, H155, H243 and W281.
PON2 and PON3 have been much less studied. Similar
to PON1, PON3 is expressed mostly in the liver and at low
levels in the kidney (Reddy et al. 2001). PON3 mRNA
and protein have been identified in murine, but not in hu-
man macrophages (Rosenblat et al. 2003). Rabbit and rat
PON3 have been purified from liver microsomes (Ozols
1999; Rodrigo et al. 2003). Rabbit and human PON3 are
found in serum associated with HDL, but about two or-
ders of magnitude less abundant than PON1 (Draganov et
al. 2000; Reddy et al. 2001). PON3 has very limited aryl-
esterase and paraoxonase activities, but shares many lac-
tone substrates with PON1 (Draganov et al. 2000). Lac-
tone hydrolysis of lovastatin, simvastatin and spironolac-
tone reported for purified human serum PON1 (Billecke
et al. 2000) was due to hPON3, present in small amounts
in the PON1 preparations (D. Draganov, J. Teiber, B.N.
La Du, unpublished observations). PON2 is not detectable
in plasma but is expressed widely in a number of tissues,
including brain, liver, kidney, testis, and may have multi-
ple mRNA forms (Mochizuki et al. 1998; Ng et al. 2001).
Dihydrocoumarin is the only substrate reported so far for
PON2 (Rosenblat et al. 2003). Like PON1, both PON2
and PON3 have been shown to prevent cell-mediated ox-
idative modification of LDL (Ng et al. 2001; Reddy et al.
2001), but the exact substrates and mechanism of their
protective activities remain to be elucidated.
PON genes
The human liver PON1 cDNA sequence has been deter-
mined by Hassett et al. (1991) and Adkins et al. (1993).
The rabbit liver PON1 sequence was reported in 1991
(Hassett et al. 1991), and the mouse liver PON1 sequence
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Fig. 3 Phylogenetic tree of
vertebrate paraoxonases. The
fungal lactone hydrolase (LH)
was used to root the tree
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in 1995 (Sorenson et al. 1995a). The three PON genes are
very closely aligned on chromosome 7 in man, and on
chromosome 6 in the mouse (Primo-Parmo et al. 1996). In
both species the three PONs contain nine exons of ap-
proximately the same length. Based on their respective
cDNA structures and the deduced amino acid sequences,
there is over 80% identity in amino acid residues in hu-
man, mouse and rabbit PON1 proteins, and at least 60%
identity between the PON 1, 2, and 3 within each of these
species (Primo-Parmo et al. 1996). All PON1s have an ex-
tra codon at position 106 (lysine in human PON1), which
is missing in PON2 and PON3 cDNAs (Primo-Parmo et
al. 1996). Polymorphic variants are common in at least the
human and rabbit PONs (Watson et al. 2001). A reason-
able conclusion from these observations is that this family
of enzymes arose by gene duplication and the PONs prob-
ably have some important physiological roles that are in-
sured by the redundancy and polymorphic forms of the
proteins. The deduced amino acid sequences of human
PON1, -2 and -3 are shown in Fig. 4.
Polymorphic forms of PON1 and PON2
Two common polymorphisms in the coding region of
hPON1 have been studied extensively in the past decade:
leucine(L)/methionine(M) at position 55 and glutamine(Q)/
arginine(R) at position 192. More attention has been paid
to the 192 polymorphism because the two allozymes dif-
fer considerably in their affinity for and catalytic activity
with a number of substrates. Paraoxon is hydrolyzed 6 times
faster by the PON1192R allozyme than by the PON1192Q al-
Fig. 4 Alignment of human
PON1, -2, and -3 amino acid se-
quences. Dashes indicate identi-
cal amino acids as in PON1. The
polymorphic sites for PON1 at
positions 55, 102, 160, and 192
are in parentheses above the se-
quence; an alternative spice vari-
ant for PON2 and the polymor-
phic sites for PON2 at positions
148 and 312 are in parentheses
below the sequence. The cys-
teines forming a disulfide bridge
in PON1 are indicated with ar-
rows; # indicates the potential
N-glycosylation sites. The aster-
isks indicate position 106 (pre-
sent only in mammalian PON1,
absent in PON2 and -3). This
numbering is in accord with La
Du et al. (1999b)
lozyme, but some organophosphates and lactones are hy-
drolyzed faster by the latter (Davies et al. 1996; Billecke
et al. 2000) (see Table 1).
The PON155M allozyme is associated with lower serum
enzymatic activity than the PON155L allozyme, but it is
not clear whether this is because of a decreased stability
of the PON155M alloenzyme, as suggested by Leviev et al.
(2001), and/or because of the linkage disequilibrium with
the –108T allele described below (Leviev and James 2000,
Brophy et al. 2001b). At least five polymorphisms have
been identified in the 5′-regulatory region of hPON1:
–108(107)T/C, –126G/C, –162A/G, –832(824)G/A and
–909(907)C/G with somewhat different effects on PON1
expression (Leviev and James 2000; Suehiro et al. 2000;
Brophy et al. 2001a); numbering differences are indicated
in parentheses, and these data are too recent for a num-
bering consensus to have been reached). Of these only the
–162, a potential nuclear factor-1 (NF-1) binding site, and
the –108, stimulating protein-1 (Sp1) binding site, lie within
consensus sequences for known transcription factors (Bro-
phy et al. 2001a). T at position –108 disrupts the GGCGGG
recognition sequence for Sp1 and results in decreased
affinity for hepatocyte nuclear extracts and Sp1 (Deakin
et al. 2003). The polymorphisms at –108C, –162A,
–832A, and –909G each affect the relative luciferase ex-
pression in vitro approximately twofold (Leviev and James
2000; Suehiro et al. 2000; Brophy et al. 2001a). These
data correlate well with higher serum PON1 levels associ-
ated with these genotypes in different populations (Leviev
and James 2000; Suehiro et al. 2000; Brophy et al. 2001b).
The analysis of the individual contribution of each poly-
morphism in the promoter region on serum paraoxonase
activity/levels is complicated because of the pronounced
linkage disequilibrium between them and the 55M/L and
192Q/R polymorphisms in the coding region. Ultimately
the –108CC genotype is associated with the highest serum
PON1 levels, –108TT with the lowest, and the heterozy-
gotes with intermediate levels (Leviev and James 2000;
Suehiro et al. 2000; Brophy et al. 2001b). In addition, four
“polymorphic” sites have been identified in the 3′-un-
translated regions of PON1 and these remain to be char-
acterized (Brophy et al. 2001b). More recently, two other
polymorphisms in the PON1 coding region have been re-
ported: isoleucine to valine at position 102 in Finns
(Marchesani et al. 2003) and arginine to glycine at posi-
tion 160 in the Chinese Han population (Wang et al. 2003).
Their presence in other populations remains unknown. At
present it is also not known whereas these polymorphisms
have any effect on PON1’s hydrolytic and/or protective
activities. All together, more than 200 single nucleotide
polymorphisms (SNPs) have been identified in the human
PON1 gene (see: http://www.ncbi.nlm.nih.gov/SNP/snp_
ref.cgi?locusId=5444), many of which are in strong link-
age disequilibrium and form certain haplotypes within the
gene (Jarvik et al. 2003). This limits the usefulness of as-
sociation studies with particular PON1 genotypes as em-
phasized in the “PON1 status” section below.
Human PON2 also has two common polymorphic sites
in the coding region: alanine/glycine at position 148 and
cysteine/serine at position 311. A higher association of the
PON2311S allele with coronary heart disease has been re-
ported (Sanghera et al. 1998; Hegele 1999; Leus et al. 2001).
However, very little is yet known about the catalytic func-
tions of human PON2, so these clinical observations are
difficult to interpret at this time.
Ethnic distribution of PON1 polymorphism
The frequency of the 192Q/R polymorphic forms of PON1
varies considerably around the world. Bimodal distribu-
tion of the levels of serum paraoxonase activity in genetic
studies of several British families (Playfer et al. 1976)
have indicated that the lower of the two modes repre-
sented exclusively people who were homozygous for a
low-activity allele. This allowed a calculation of the fre-
quency of both alleles (low activity and high activity) that
was adequate for estimating PON1gene frequencies in the
bimodal population samples of Northern Europe, Canada
and the USA (La Du 1992). The low-activity phenotype
has been shown subsequently to represent homozygosity
for the PON1192Q allozyme, whereas the high paraoxonase
activity phenotype represents the combination of the het-
erozygotes and the homozygotes for the PON1192R allele
(Adkins et al. 1993; Humbert et al. 1993). The above para-
oxonase activity phenotyping method did not distinguish
adequately between heterozygotes and homozygotes for
the high-activity allele (Eckerson et al. 1983), and it was
not appropriate for most African, Near-Eastern and Far-
Eastern population samples, since paraoxonase activities in
those regions are not distributed bimodally (Geldmacher-
von Mallinckrodt and Diepgen 1988; La Du 1992). An-
other method of phenotyping has been developed on the
basis of the ratio of the paraoxonase activity (at pH 10.5 in
presence of 1 M NaCl) and the arylesterase activity with
phenylacetate (Eckerson et al. 1983), given that arylesterase
activity is directly proportional to PON1 serum concentra-
tion, regardless of the genotype. This method gave tri-
modal distributions with values (ratios) for the first mode
of about 1.2, for the second of around 4.7, and for the third
about 8.4, corresponding respectively to the low-activity
homozygotes, heterozygotes and high-activity allele homo-
zygotes. After elucidating the molecular basis (PON1Q192R)
for paraoxonase polymorphism, this method was vali-
dated later by genotyping of the same samples (Adkins et
al. 1993). Other activity ratios have also been developed
and used in much the same way, for example, chlorpyrifos
oxon with paraoxon (Davies et al. 1996) or diazoxon and
paraoxon (Richter and Furlong 1999). Some examples
follow (Table 2) to illustrate the divergent frequencies of
the PON1192R and PON1192Q alleles in different ethnic and
geographic regions of the world. The R allele is most fre-
quent in Central Africa and in some aboriginal or isolated
regions, whereas the Q allele has become more frequent
in the temperate regions of Europe and North America. To
what degree this distribution represents the migration of
the populations, or the influence of the local climate and
environmental factors must still be determined.
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“PON1 status”
PON1 serum levels differ significantly between individu-
als (up to 13-fold) and are modulated by disease state, di-
etary, life-style, and environmental factors (Costa et al.
2003). With the technological advancements available to-
day it is very easy to determine particular PON1 geno-
types directly by DNA sequencing, PCR amplification/re-
striction enzyme analysis, real time fluorescent PCR with
melting point analysis etc. However, the phenotyping ra-
tio methods, outlined above, provide a direct quantitative
measure of the functional effects of the usual or variant
forms of the PON1 with different substrates. This addi-
tional information referred as the “PON1 status” (Richter
and Furlong 1999) supplies a broader basis than the geno-
type, alone, for correlation with disease susceptibility, or
responsiveness to environmental agents (Furlong 2000;
La Du et al. 2001; Brophy et al. 2002). Thus the catalytic
efficiency of each PON1192 allozyme must be considered,
as well as the level of that particular allozyme. PON1192QR
heterozygous individuals have a mixture of the two iso-
forms, and in some heterozygotes, there will be a higher
level of one of the two allelic types than is present in some
individuals homozygous for that allozyme (it is incorrect
to assume that all heterozygotes have one-half of the av-
erage level of each allozyme). If the two allelic forms of
the enzyme differ greatly in their catalytic efficiencies, the
contribution of each allelic form should be evaluated with
respect to toxicity from environmental chemicals (La Du
et al. 2001).
PON1 and cardiovascular disease
The special localization of the PON1 in the HDL complex of
human serum led to the suggestion by Mackness (1989a,
1989b) that the enzyme might play an important physio-
logical role in lipid metabolism and protect against the de-
velopment of atherosclerosis. This speculation has stimu-
lated many important investigations over the past decade
with considerable evidence that PON1 may protect vascu-
lar tissues from oxidative damage (Aviram 1999; Durring-
ton et al. 2001). An additional important clue to a physio-
logical function for PON1 has been provided by studies
with mice lacking this enzyme (Shih et al. 1998). The
“knock-out” mice develop atherosclerosis when fed an athero-
genic diet, and their HDL, in contrast to wild-type HDL,
fails to prevent LDL oxidation in cultured artery wall cells
(Shih et al. 1998). Purified PON1 shows the expected pro-
tection against oxidative damage from LDL (Aviram et al.
1998; Navab et al. 2002). Furthermore, purified rabbit
serum PON3 has recently been found to be even more
protective than PON1 against copper-induced LDL oxida-
tion (Draganov et al. 2000). Although the lactonase activ-
ity of some model compounds seems to parallel roughly
the degree of protection against oxidative damage, it is
not clear whether these two activities are related directly.
Perhaps protection involves the hydrolysis, and thereby
the inactivation of some potentially toxic endogenous lac-
tones. Such questions will be answered by future research.
A brief summary of possible mechanisms by which PONs
may protect against cardiovascular disease and athero-
sclerosis is given in Table 3.
Many clinical papers have been published in the past
decade, most supporting, but some excluding, a relation-
ship between the PON1 polymorphisms and the develop-
ment of cardiovascular disease and atherosclerosis (re-
viewed in Heinecke and Lusis 1998; Hegele 1999; Dur-
rington et al. 2001; Brophy et al. 2002; Shih et al. 2002;
Costa et al. 2003). The frequent association of PON1192R
with vascular disease predicts decreased efficiency for
this allozyme in the metabolism of oxidized lipids and/or
less stability compared with PON1192Q. Evidence for both
has been provided experimentally (Mackness et al. 1998;
Aviram et al. 1998, 2000). However, as pointed out in the
previous section, serum PON1 level/activity is also an im-
portant variable and most probably a better predictor of
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Table 2 Geographic and eth-
nic distribution of human
PON1 polymorphisms
1Modified from La Du (1992)
2Genotyping studies from mul-
tiple sources, for an extensive
list of relevant references see
Brophy et al. (2002)
3From Leviev and James
(2000); Suehiro et al. (2000);
Brophy et al. (2001b)
Geographic region % of population Q192 allele L55 allele –108C allele 
with low activity1 frequency2 frequency2 frequency3
North America Caucasian 51–52 0.70–0.72 0.64 0.50
Afro-American 15 – – –
Europe (Caucasian) 53 0.67–0.74 0.57–0.64 0.46
Africa 0–20 – – –
Near East 35–50 – – –
Far East 10–20
Chinese – 0.36–0.43 0.96 – 
Japanese 10 0.38–0.41 0.91–0.94 0.48 
Australia Caucasian – 0.63 0.60 – 
Aborigines 0 – – –
Table 3 Evidence for human PON1 antiatherogenicity (summa-
rized from Aviram 1999; Durrington et al. 2001; Navab et al. 2002)
1. Protects HDL against oxidation and preserves its functions
↑ cellular cholesterol efflux from macrophages
2. Protects LDL against oxidation
↓ lipid peroxides
3. Ameliorates effects of oxidized LDL
↓ inflammatory and cytotoxic oxidized phospholipids
↓ LDL uptake by macrophages
↓ monocyte transmigration induced by oxidized LDL
4. Decreases lipid peroxides in atherosclerotic lesions
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the risk of cardiovascular disease (Jarvik et al. 2000; Mack-
ness et al. 2001). In a recent study Jarvik et al. (2003) have
demonstrated that PON activity predicts carotid artery
disease, yet four PON1 functional polymorphisms do not.
Future studies of low-activity PON1 patients may reveal
how PON1 protects against cardiovascular disease (La Du
2003).
PON1 and other diseases
Most of the recent research efforts to determine a physio-
logical role for PON1 (and possibly the other PONs) have
focused on atherosclerosis and cardiovascular diseases.
However, it is logical to extend the proposed protective
mechanism of PON1 against oxidative vascular damage
to other organs and tissues.
Low serum PON1 activity has been found in diabetes
mellitus (both type I, insulin-dependent, and type II, non-
insulin-dependent) and renal disease (reviewed in Mack-
ness et al. 2002a). In most studies the lowest PON1 levels
have been found in patients with vascular complications,
but causal relationships remain to be estimated. In type-I
diabetic patients low PON1 levels and activity, indepen-
dent of PON1 55 and 192 polymorphisms, have been found
(Boemi et al. 2001; Mackness et al. 2002b). Diabetic com-
plications in Japanese population, such as retinopathy (Kao
et al. 1998) or central retinal vein occlusion (Murata et al.
1998), may be associated with the PON155L and PON1192R
allozymes, respectively. A higher frequency of the PON1192R
allele has been reported in type-II diabetic patients with
macrovascular disease (Hu et al. 2003), cerebrovascular
disease (Koch et al. 2001), and coronary artery disease
(Osei-Hyiaman et al. 2001). Noteworthy is that the asso-
ciation of the PON1192R genotype with an increased risk
of vascular disease is more prominent in patients with ac-
companying disease (e.g., diabetes) and/or in Eastern
populations, in which the PON1192R allele is prevalent.
No association between Parkinsonism and PON1 192
polymorphism was found by a Russian laboratory (Akhme-
dova et al. 1999), but a significant increase in the PON1192R
allele was noted in a Japanese study (Kondo and Yama-
moto 1998). The implication in the latter study is that
PON1192R allozyme is less effective against some environ-
mental neurotoxins than PON1192Q. No association of
PON1 55 and 192 polymorphisms have been found for
Alzheimer’s disease or vascular dementia (Dantoine et al.
2002; Paragh et al. 2002; Pola et al. 2003), but PON 
levels are lower in patients with dementia than in age-
matched controls (Paragh et al. 2003). A lower PON1192R
frequency in patients with sporadic Alzheimer’s disease,
but a higher PON1192R frequency in patients with coronary
artery disease, has been found by Scacchi et al. (2003).
Haley et al. (1999) have reported a comparison of a small
number of Gulf War Veterans with neurological symp-
toms with unaffected or non-deployed controls showed
that the level of the PON1192Q allozyme activity was low-
est (or was PON1192R) in those most severely affected.
Different sensitivities to some neurotoxins might be ex-
plained if certain toxins are hydrolyzed more efficiently
by human PON1192Q than by the PON1192R allozyme.
Systemic infection and inflammation reduce serum PON1
levels and expression (Feingold et al. 1998; Van Lenten et
al. 2001; Kumon et al. 2002). These changes are accom-
panied with alterations in other HDL associated proteins
(e.g., apolipoprotein A-I, lecithin:cholesterol acyltransferase,
cholesterol ester transfer protein), and could decrease the
ability of HDL to protect against atherosclerosis. Bog-
Hansen et al. (1978) have suggested that PON1 might pro-
tect against bacterial endotoxins. Purified PON1192Q ap-
plied before or shortly after injection of mice with a lethal
dose of lipopolysaccharide rescued 60% and 30% of the
animals, respectively (La Du et al. 1999a). The role of
PON1 in human and experimental animal models of sep-
sis are currently under investigation in the author’s labo-
ratory.
Conclusions
Serum paraoxonase (PON1) and the other members of the
PON family of enzymes are conserved, closely related
proteins of uncertain function and physiological signifi-
cance. PON1’s organophosphatase and arylesterase activ-
ities, which utilize mostly human-made chemicals, seem
to be ancillary rather than primary function of the en-
zyme: natural organophosphates such as anatoxin-a, for
example, are not hydrolyzed by PON1 (LaDu et al. 1999a).
In contrast, lactonase/lactonizing activities utilize natural
substrates and are shared by all three PONs and their ho-
mologues. This redundancy within these closely related
enzymes suggests that they may share other important hy-
drolytic activities. Generation of PON2 and PON3 “knock-
out” mice is currently underway and may help to uncover
their (patho)physiological roles. The belief that PON1 has
the ability to prevent oxidative damage to tissues in gen-
eral seems to be a reasonable hypothesis, but little con-
crete evidence, except for atherosclerosis studies, is yet
available to support it. A monograph on PON1’s role in
health and disease has been published recently (Costa and
Furlong 2002).
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